D., & Haqq, A
Signal Transduct
A thoughtful evaluation can help determine whether the issue is purely metabolic, partly orthopedic, or both
Gromada J, Ma X, Hoy M et al (2004) ATP-sensitive K+ channel-dependent regulation of glucagon release and electrical activity by glucose in wild-type and SUR1-/- mouse alpha-cells
MARKET ECOSYSTEM The GLP-1 agonists ecosystem encompasses a network of interdependent stakeholders, including drug manufacturers, contract research and manufacturing organizations, healthcare providers, and end users
Incretin-based therapies work either by preventing enzymatic degradation of GLP-1, thus maintaining plasma levels of endogenous GLP-1 (dipeptidyl peptidase 4 inhibitors, DPP4is) or by directly activating GLP-1 receptors and mimicking the action of native GLP-1 (glucagon-like peptide-1 receptor agonists, GLP-1 RAs) [9]